Description
What is Anastrozole?
Anastrozole is a third-generation non-steroidal aromatase inhibitor and a benzyltriazole small molecule. It is a potent, selective, reversible inhibitor of aromatase (CYP19A1), the cytochrome-P450 enzyme that catalyzes the terminal step of estrogen biosynthesis. Supplied as 1mg oral tablets for reference and pre-clinical laboratory study of estrogen-biosynthesis pathways and endocrine feedback.
How Anastrozole works (research context)
Anastrozole reversibly coordinates with the heme iron at the active site of aromatase (CYP19A1) through its triazole nitrogen, competitively blocking the cytochrome-P450 catalytic cycle that converts C19 androgens to C18 estrogens. By suppressing this aromatization step in model systems it lowers estrogen formation. Being non-steroidal and reversible, it does not covalently inactivate the enzyme.
Research applications
- Reference aromatase (CYP19A1) inhibitor in estrogen-biosynthesis assays
- In-vitro study of androgen-to-estrogen conversion and steroidogenic flux
- Pre-clinical models of estrogen-dependent endocrine feedback
- Comparative pharmacology versus steroidal aromatase inhibitors
Key facts
- Third-generation non-steroidal, reversible aromatase inhibitor
- Targets CYP19A1, the terminal enzyme of estrogen biosynthesis
- Benzyltriazole chemotype coordinating the heme iron at the active site
- Supplied as 1mg oral tablets for reference research use
Product specifications
- Class: Non-steroidal aromatase (CYP19A1) inhibitor, small molecule
- Also known as: Anastrozole; third-generation non-steroidal aromatase inhibitor
- Form: Oral tablets
- Verification: Identity and quality checked per batch
- Documentation: Certificate of analysis per batch
- Storage: Store tablets at controlled room temperature in a dry, light-protected container.
For laboratory research use only. Not for human or veterinary use, consumption, diagnostic, or therapeutic purposes.









Dr. Cecilia Marsh (verified owner) –
Anastrozole reference tablets — HPLC matched the 1mg assay and the COA was complete. Clean aromatase (CYP19A1) inhibition in our estrogen-biosynthesis assay.
T. Bello (verified owner) –
Good material and clear potency documentation. Tablets a little small to handle but assay-confirmed. Shipping prompt.
Rosa Giordano (verified owner) –
COA matched, blister sealed, discreet box. Exactly the reference reagent our CYP19A1 work needed.
Dr. Annika Voss (verified owner) –
Benchmark non-steroidal aromatase inhibitor in our comparative panel — behaved exactly as characterized. Trustworthy lot.
Pavel Horák (verified owner) –
Consistent benzyltriazole reference, reversible inhibition confirmed in our microsomal assay. Reliable for steroidogenic-flux work.